Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosupressandid - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukeemia, müelogeenne, krooniline, bcr-abl positiivne - antineoplastilised ained - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosupressandid - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosuppressants, valikuline immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 28tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 84tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 14tk; 14mg 98tk; 14mg 28tk; 14mg 30tk

Eesti - eesti - Ravimiamet

gedeon richter plc. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 14tk; 14mg 98tk; 14mg 84tk

Eesti - eesti - Ravimiamet

zentiva k.s. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 14tk; 14mg 28tk; 14mg 84tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.